Holen Sie sich die Stockscreener-App
99.29
3.23%
-3.3765
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
HC Wainwright Brokers Lift Earnings Estimates for Nuvalent - MarketBeat
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Nuvalent Executives Sell Shares Under Trading Plan - TradingView
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise - Stock Titan
Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech With A Promising 40.78% Upside Potential - DirectorsTalk Interviews
UBS Adjusts Price Target on Nuvalent to $138 From $132, Maintains Buy Rating - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Finviz
Does Nuvalent (NUVL) Have a Chance to Surge by 37.26% According to Wall Street Analysts? - Bitget
Nuvalent (NASDAQ:NUVL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Vanguard Group Inc. Raises Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug - Investing.com Australia
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - The Malaysian Reserve
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug By Investing.com - Investing.com South Africa
Nuvalent, Inc. SEC 10-K Report - TradingView
Nuvalent (NUVL) targets 2026 launches with ROS1 and ALK lung cancer drugs - Stock Titan
(NUVL) Risk Channels and Responsive Allocation - Stock Traders Daily
Nuvalent (NUVL) details 2025 results and key FDA milestones - Stock Titan
BRIEF-Nuvalent Q4 EPS USD -1.58 - TradingView
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - The Motley Fool
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 41.94% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Trust linked to Nuvalent (NUVL) files Form 144 to sell 1,650 shares - Stock Titan
Bank Watch: Is Nuvalent Inc forming a bullish divergenceMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
(NUVL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans - MarketBeat
NUVL: Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion - TradingView
Nuvalent honors women pioneers on Women in Science Day - Traders Union
Candriam S.C.A. Purchases 28,462 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing - Yahoo Finance
US Stocks Recap: Is Nuvalent Inc forming a bullish divergenceJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 – Company Announcement - Financial Times
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Barchart.com
Liquidity Mapping Around (NUVL) Price Events - Stock Traders Daily
Nuvalent, Inc. (NUVL) Investor Outlook: Biotechnology Innovator with a 37.73% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL): Investor Outlook With A 33% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Final Week: Is Nuvalent Inc benefiting from innovation trendsBreakout Watch & Long-Term Growth Plans - baoquankhu1.vn
Why (NUVL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 14,300 Shares of Stock - MarketBeat
Deborah Ann Miller Sells 700 Shares of Nuvalent (NASDAQ:NUVL) Stock - MarketBeat
Nuvalent Inc stock hits 52-week high at 112.89 USD By Investing.com - Investing.com Australia
4.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):